Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5-year follow-up study
| Autor: | Sadik Aksit, Ayten Egemen, Zafer Kurugöl, Selda Erensoy, Altınay Bilgiç |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Male
HBsAg Pediatrics medicine.medical_specialty Time Factors Hepatitis B vaccine Injections Intradermal Turkey Immunization Secondary Booster dose medicine.disease_cause medicine Humans Hepatitis B Vaccines Hepatitis B Antibodies Child Immunization Schedule Hepatitis B virus Vaccines Synthetic General Veterinary General Immunology and Microbiology biology business.industry Public Health Environmental and Occupational Health Infant Titer Infectious Diseases El Niño Child Preschool Immunology biology.protein Molecular Medicine Female Viral disease Antibody business Immunologic Memory Follow-Up Studies |
| Zdroj: | Vaccine. 19:3936-3939 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/s0264-410x(01)00118-9 |
| Popis: | Several studies have documented the efficacy of low-dose intradermal administration of hepatitis B vaccine. However, little is known about the duration of protection provided by low-dose intradermal administration of hepatitis B vaccine. This study reports results from a 5-year follow up period of 200 healthy children (100 infants and 100 preschool children) immunized intradermally with 2 microg doses of recombinant hepatitis B vaccine (GenHevac B) at months 0,1, and 6. In the 8th week after the third vaccine dose, 97% of the children developed anti-HBs antibodies higher than or equal to 10 mlU ml(-1), and the antiHBs geometric mean titre (GMT) was 676 mlU ml(-1). In month 18 and year 5, the anti-HBs GMT decreased to approximately one-third (220 mlU ml(-1)) and one-tenth (68 mlU ml(-1)) of the initial levels, respectively. However, 87% of the children had protective levels of anti-HBs (> or =10 mlU ml(-1)) after 5 years. Among 156 children followed for 5 years, none became positive for anti-HBc and/or HbsAg. Seven children who were seronegative after 5 years developed anti-HBs antibodies higher than 1000 mlU ml(-1) after an additional 10 microg intramuscular hepatitis B vaccine. Persistent immunologic memory over periods of 5 years or more is evident, the anamnestic antibody response to a booster dose of vaccine, even in these children who have lost antibody. We conclude that intradermal administration of 2 microg recombinant hepatitis B vaccine provides long-term protection against hepatitis B virus in infants and preschool children. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect